Istiratumab
- CAS No.
- 1509928-04-4
- Chemical Name:
- Istiratumab
- Synonyms
- Istiratumab;Research Grade Istiratumab;Research Grade Istiratumab (DHC29907)
- CBNumber:
- CB48080936
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
- TDS File:
- TDS
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | XLR461MD3M |
Istiratumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0628914 | Istiratumab 98.45% | 1509928-04-4 | 1mg | $812 | 2026-06-04 | Buy |
| ChemScene | CS-0628914 | Istiratumab 98.45% | 1509928-04-4 | 5mg | $2275 | 2026-06-04 | Buy |
| ChemScene | CS-0628914 | Istiratumab 98.45% | 1509928-04-4 | 10mg | $3629 | 2026-06-04 | Buy |
| aablocks | AA02F5VC | ISTIRATUMAB >98% | 1509928-04-4 | 1mg | $869 | 2026-06-03 | Buy |
| aablocks | AA02F5VC | ISTIRATUMAB >98% | 1509928-04-4 | 5mg | $2369 | 2026-06-03 | Buy |
Istiratumab Chemical Properties, Uses, Production
Uses
Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers[1][2][3].
References
[1] Kundranda M, et al. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). Ann Oncol. 2020 Jan;31(1):79-87. DOI:10.1016/j.annonc.2019.09.004
[2] Camblin AJ, et al. Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer. Clin Cancer Res. 2018 Jun 15;24(12):2873-2885. DOI:10.1158/1078-0432.CCR-17-2262
[3] Camblin AJ, et al. Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer. Sci Rep. 2019 Nov 14;9(1):16832. DOI:10.1038/s41598-019-53322-y
Istiratumab Preparation Products And Raw materials
Raw materials
Preparation Products
Istiratumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7283 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
| Shanghai jerryxing Biomedical Technology Co., Ltd | 17521512546 17721492509 | 460170712@qq.com | China | 4996 | 58 |
| Changsha Fuzhen Biotechnology Co.，LTD | 15111215862 18229892877 | 3062105966@qq.com | China | 5569 | 58 |
| Olix ( Hubei) Pharmaceutical Technology Co., Ltd | 17316404525 17316404525 | 209533805@qq.com | China | 9769 | 58 |
| Atagenix Laboratories | 027-87008169 17762441161 | info@atagenix.com | China | 9997 | 58 |
